HIV infected T cell

Promising drug target could restore immune system’s ability to fight HIV

Scientists in NCI’s Center for Cancer Research have identified a new target for drugs that could help people who are HIV-positive eliminate recalcitrant pools of the virus. The research findings were published January 5 in Science. Read more…

Lowy and Schiller

Doug Lowy and John Schiller receive the Szent-Györgyi Prize for Progress in Cancer Research

Posted: Feb 15, 2018

The National Foundation for Cancer Research (NFCR) will honor CCR’s Doug Lowy, M.D., Chief of the Laboratory of Cellular Oncology, and John Schiller, Ph.D., Deputy Chief of the Laboratory of Cellular Oncology, with the Szent-Györgyi Prize for Progress in Cancer Research during a ceremony on May 5 in Washington, D.C. The annual prize, named after NFCR’s co-founder, Albert Szent-Györgyi, M.D., Ph.D., honors scientists who have made an original discovery or breakthrough in scientific understanding that has had a lasting impact on the cancer field and saving people’s lives. In addition to the more than 150 papers co-authored by Drs. Lowy and Schiller, the duo’s research has led to great advances in understanding HPV infection and the development of three preventive HPV vaccines approved by the U.S. Food and Drug Administration. Read more…

Doug Lowy and John Schiller receive the Szent-Györgyi Prize for Progress in Cancer Research
Children's Inn logo

Pediatric patients featured in NIH Children’s Inn 2017 Annual Report

Posted: Feb 14, 2018

Lucy was diagnosed with Hyper IgE syndrome or Job’s syndrome – a rare genetic illness that puts her at risk for developing serious lung and skin infections. Avery has a rare NFKB1 gene mutation that compromises her immune system. For both patients, clinical trials at the Center for Cancer Research provided life-saving bone marrow transplants to address infections caused by immune deficiencies. Lucy and Avery stay at The Children’s Inn when they come to NIH for treatment. Read Lucy’s story (page 3) and Avery’s story (page 5) in the Children’s Inn Annual Report…

Pediatric patients featured in NIH Children’s Inn 2017 Annual Report
Staff Scientists and Staff Clinicians logo

14th Annual CCR and DCEG Staff Scientist and Staff Clinician Retreat

Posted: Feb 13, 2018

The NCI Center for Cancer Research (CCR) and Division of Cancer Epidemiology and Genetics (DCEG), and the Frederick National Laboratory for Cancer Research (FNLCR) will hold their 14th Annual Retreat for all Staff Scientists and Staff Clinicians on April 6, 2018. This year's topic is "Cutting Edge in Cancer Research: Cancer Immunotherapy"The registration deadline is February 23 and abstracts must be submitted by February 15Learn more...

14th Annual CCR and DCEG Staff Scientist and Staff Clinician Retreat
NCI's Shady Grove campus in Rockville, Maryland

18th Annual CCR Fellows and Young Investigators Colloquium

Posted: Feb 13, 2018

The 18th Annual Fellows and Young Investigators Colloquium will be held on March 1-2, 2018 on the NCI Shady Grove campus.  The Colloquium is open to all NCI fellows and trainees, including postdoctoral fellows, clinical fellows, post-baccalaureate fellows, and graduate students. Registration and awards are generously funded by the Office of the Director, CCR.  Learn more...

18th Annual CCR Fellows and Young Investigators Colloquium
ASCO logo

CCR scientists help develop first recommendations for managing mesothelioma

Posted: Feb 7, 2018

Anish Thomas, M.B.B.S., M.D., Investigator in the Developmental Therapeutics Branch, Markku Martti Miettinen, M.D., Ph.D., Senior Clinician in the Laboratory of Pathology, and Raffit Hassan, M.D., Co-Chief of the Thoracic and Gastrointestinal Oncology Branch, are among the contributing authors of the American Society of Clinical Oncology’s first guidelines for evidence-based recommendations on the management of mesothelioma. The guidelines were informed by 222 relevant studies. The recommendations were developed for diagnosis, staging, chemotherapy, surgical cytoreduction, radiation therapy and multimodality therapy in patients with mesothelioma. Learn more…

CCR scientists help develop first recommendations for managing mesothelioma
Xenograft Model of Prostate Cancer

Clinical trial tests new schedule of radiation therapy for recurring prostate cancer

Posted: Feb 6, 2018

In order to find the most compressed schedule of radiation that prostate cancer patients can tolerate without strong side effects, Deborah Citrin, M.D., of the Radiation Oncology Branch wants to see if giving higher doses of radiation over 2–4 weeks can be as effective at killing cancer cells. Read more… 

Clinical trial tests new schedule of radiation therapy for recurring prostate cancer
Kenneth Aldape, M.D.

Ken Aldape joins CCR as Chief, Laboratory of Pathology

Posted: Feb 5, 2018

Kenneth Aldape, M.D., has joined CCR as the Chief of the Laboratory of Pathology. Dr. Aldape’s research interests focus on the molecular pathogenesis and classification of brain tumors, particularly malignant gliomas and meningliomas. His passion is to apply new molecular technologies to classify tumors from a biological perspective. Learn more...

Ken Aldape joins CCR as Chief, Laboratory of Pathology
Cartoon illustrating how SLFN11acts like an alarm clock against abnormal DNA replication in a DNA-damaged cell

Study characterizes how DNA-damaging anti-cancer drugs kill cancer cells

Posted: Feb 2, 2018

Patients whose cancer cells express the SLFN11 protein are more likely to respond to DNA-damaging anti-cancer drugs than those whose cancer cells don’t express SLFN11. In a new study, Center for Cancer Research investigators show how these drugs recruit SLFN11 to block replication and kill cancer cells. Read more…

Study characterizes how DNA-damaging anti-cancer drugs kill cancer cells
child artwork

Pediatric Precision Oncology Conference

Posted: Feb 2, 2018

This conference, held March 4-7, 2018 in Scottsdale, AZ, will bring together internationally recognized experts in the field of pediatric oncology for a collective conversation on key discoveries and publications in genomics, epigenetics, immunotherapy and big data collection for children and adolescents with cancer.  CCR’s Javed Khan, M.D., Deputy Chief of the Genetics Branch, and Terry Fry, M.D., former Investigator in the Pediatric Oncology Branch, are among the conference speakers. This event is co-sponsored by CCR. Learn more and register…

Pediatric Precision Oncology Conference
Holding hands

Clinical trial studies drug for pediatric diffuse intrinsic pontine glioma (DIPG) treatment

Posted: Jan 31, 2018

Diffuse intrinsic pontine gliomas (DIPGs) are difficult to treat and are the leading cause of brain tumor deaths in children. Katherine Warren, M.D., of the Pediatric Oncology Branch is leading a pediatric clinical trial to determine the safety and best dose of panobinostat, a histone deacetylase inhibitor, for slowing or stopping the growth of DIPGs. Read more…

Clinical trial studies drug for pediatric diffuse intrinsic pontine glioma (DIPG) treatment

Pages